Compass Pathways
British biotechnology company developing psilocybin-based treatments for mental health disorders
CMPS Nasdaq
ISIN US20451W1018 SEC CIK 1816590
Follow Compass Pathways
Weekly email: filings, results
Net income
−$9.8M
+92.9% vs same quarter last year
EPS, diluted
−$0.31
+78.5% vs same quarter last year
Operating cash flow
−$50.8M
−44.6% vs same quarter last year
Operating income
−$56.4M
−39.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$269.8M |
| FY24 | −$155.1M |
| FY23 | −$118.5M |
| FY22 | −$91.5M |
| FY21 | −$71.7M |
| FY20 | −$60.3M |
| FY19 | −$19.6M |
| FY18 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | −$119.2M |
| FY23 | −$97.4M |
| FY22 | −$106M |
| FY21 | −$68.1M |
| FY20 | −$41.5M |
| FY19 | −$18M |
| FY18 | - |